VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Status:
COMPLETED
Trial end date:
2025-08-15
Target enrollment:
Participant gender:
Summary
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI 30 kg/m2) or who are overweight (BMI 27 kg/m2) with at least one weight-related co-morbid condition.
VK2735 or matched placebo will be administered once daily.